Sucampo Pharmaceuticals, Inc. Acquires Sucampo AG for $80M

Sucampo Pharmaceuticals, Inc. SCMP today announced the acquisition of Sucampo AG (SAG) and its wholly-owned subsidiary, Sucampo AG Japan (SAGJ), from Ryuji Ueno, M.D., Ph.D., Ph.D., and Sachiko Kuno, Ph.D., co-founders and majority shareholders of Sucampo Pharmaceuticals, Inc. (SPI). The total purchase price is $80.0 million, consisting of a cash payment of $28.1 million at closing, and a 7-year subordinated unsecured promissory note of $51.9 million. In addition, the purchase price will be increased by an amount equal to 15%, up to a maximum of $40.0 million, of any cash that may be received by SPI in connection with the current arbitration proceedings initiated by SPI against Takeda Pharmaceutical Company Limited.